Ledipasvir and sofosbuvir for HCV infection in patients coinfected with HBV

Antiviral Therapy

Volumn 21, Issue 7, 2016, Pages 605-609

  Gane, Edward J ^a,b   Hyland, Robert H ^c   An, Di ^c   Svarovskaia, Evguenia S ^c   Brainard, Diana ^c   McHutchison, John G ^c  

^a Auckland Clinical Studies   (New Zealand)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

^c GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; HEMOGLOBIN; HEPATITIS B ANTIGEN; LEDIPASVIR PLUS SOFOSBUVIR; VIRUS DNA; VIRUS RNA; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR; SOFOSBUVIR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BODY MASS; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; GENOTYPE; GLOMERULUS FILTRATION RATE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MIXED INFECTION; PILOT STUDY; POLYMERASE CHAIN REACTION; POLYNESIAN; PRIORITY JOURNAL; RACE; RHINORRHEA; SIDE EFFECT; SNEEZING; THORAX PAIN; THROMBOCYTE COUNT; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; VIRUS RESISTANCE; AGED; BLOOD; COMBINATION DRUG THERAPY; VIROLOGY;

AGED; ANTIVIRAL AGENTS; BENZIMIDAZOLES; COINFECTION; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; FLUORENES; HEPATITIS B; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; SOFOSBUVIR;

EID: 85006131623     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP3066     Document Type: Article

References (13)

1. Liu C-J, Chen P-J. Updates on the treatment and outcomes of dual chronic hepatitis C and B virus infection. World J Gastroenterol 2014; 20:2955-2961.
2. Liaw Y-F, Chen Y-C, Sheen I-S, Chien R-N, Yeh C-T, Chu C-M. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology 2004; 126:1024-1029.
3. Chu C-J, Lee S-D. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol 2008; 23:512-520.
4. Dianzani F. Viral interference and interferon. Ric Clin Lab 1975; 5:196-213.
5. Konstantinou D, Deutsch M. The spectrum of HBV/HCV coinfection: epidemiology, clinical characteristics, viral interactions and management. Ann Gastroenterol 2015; 28:221-228.
6. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014; 60:392-420.
7. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015; 63:199-236.
8. Potthoff A, Berg T, Wedemeyer H, HEP-NET B/C Coinfection Study Group. Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin. Scand J Gastroenterol 2009; 44:1487-1490.
9. Yu M-L, Lee C-M, Chen C-L, et al. Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up. Hepatology 2013; 57:2135-2142.
10. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370:1483-1493.
11. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370:1889-1898.
12. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370:1879-1888.
13. Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, Phase 3 trial. Lancet Infect Dis 2015; 15:645-653.